Drug classes vs placebo for improvement in dyspeptic symptom scores*
| Weighted event rates | ||||||
|---|---|---|---|---|---|---|
| Drug class | Number of trials | Number of patients | Active drug | Placebo | RBI (95% CI) | NNT (CI) |
| *H2RAs = histamine-2 receptor antagonists. Treatment duration was 2 to 6 weeks for prokinetics and H2RAs and 4 weeks for pirenzepine. Other abbreviations defined in glossary; RBI, NNT, and CI calculated from data in article. | ||||||
| †11 of the 12 prokinetics trials evaluated cisapride. | ||||||
| Prokinetics†| 12 | 829 | 75% | 44% | 50% (30 to 65) | 4 (3 to 6) |
| H2RAs | 8 | 1225 | 71% | 51% | 30% (4 to 48) | 6 (5 to 9) |
| Antimuscarinics (pirenzepine) | 2 | 163 | 79% | 58% | 50% (19 to 69) | 5 (3 to 14) |